Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
186.5 NOK | +0.81% | +4.19% | -12.85% |
Apr. 25 | Transcript : Medistim ASA, Q1 2024 Earnings Call, Apr 25, 2024 | |
Apr. 24 | Medistim ASA Approves Dividend for the Year 2023, Payable on May 6, 2024 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- With an expected P/E ratio at 31.78 and 28.89 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.85% | 317M | - | ||
+10.22% | 226B | B | ||
+12.99% | 198B | B- | ||
+18.09% | 142B | B- | ||
+28.66% | 111B | A- | ||
+2.09% | 65.26B | A- | ||
+14.70% | 54.36B | B+ | ||
+6.68% | 50.94B | B+ | ||
+8.29% | 44.8B | A | ||
+2.60% | 36.8B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MEDI Stock
- Ratings Medistim ASA